MX2016005003A - Marcadores geneticos predictivos de respuesta al acetato de glatiramero. - Google Patents
Marcadores geneticos predictivos de respuesta al acetato de glatiramero.Info
- Publication number
- MX2016005003A MX2016005003A MX2016005003A MX2016005003A MX2016005003A MX 2016005003 A MX2016005003 A MX 2016005003A MX 2016005003 A MX2016005003 A MX 2016005003A MX 2016005003 A MX2016005003 A MX 2016005003A MX 2016005003 A MX2016005003 A MX 2016005003A
- Authority
- MX
- Mexico
- Prior art keywords
- glatiramer acetate
- response
- genetic markers
- markers predictive
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona un método para tratar un sujeto humano que padece de esclerosis múltiple o un ataque clínico individual consistente con esclerosis múltiple con una composición farmacéutica que comprende acetato de glatirámero y un portador farmacéuticamente aceptable, que comprende los pasos de: (i) determinar un genotipo que corresponde a los polimorfismos de nucleótidos que consisten de: Grupo 1 del sujeto en una ubicación de uno o más (SNPs) individuales seleccionados del grupo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361893807P | 2013-10-21 | 2013-10-21 | |
US201462048127P | 2014-09-09 | 2014-09-09 | |
US201462048641P | 2014-09-10 | 2014-09-10 | |
PCT/US2014/061647 WO2015061367A1 (en) | 2013-10-21 | 2014-10-21 | Genetic markers predictive of response to glatiramer acetate |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016005003A true MX2016005003A (es) | 2016-08-03 |
Family
ID=52826364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016005003A MX2016005003A (es) | 2013-10-21 | 2014-10-21 | Marcadores geneticos predictivos de respuesta al acetato de glatiramero. |
Country Status (13)
Country | Link |
---|---|
US (2) | US9702007B2 (es) |
EP (1) | EP3060681A4 (es) |
JP (1) | JP2016540729A (es) |
KR (1) | KR20160098199A (es) |
CN (1) | CN105658818A (es) |
AU (1) | AU2014340247A1 (es) |
CA (1) | CA2926724A1 (es) |
EA (1) | EA201690759A1 (es) |
IL (1) | IL244783A0 (es) |
MX (1) | MX2016005003A (es) |
TW (1) | TW201610166A (es) |
UY (1) | UY35790A (es) |
WO (1) | WO2015061367A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
NZ609938A (en) | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
JP2014530819A (ja) | 2011-10-10 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | 酢酸グラチラマーに対する臨床的応答性を予測するために有用な一塩基多形 |
EP2906719A4 (en) | 2012-10-10 | 2016-11-09 | Teva Pharma | PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
CR20210001A (es) | 2018-07-10 | 2021-04-19 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteina con dedos de zinc 2 de la familia ikaros (1kzf2) |
CN111088368B (zh) * | 2019-12-30 | 2021-04-16 | 山西医科大学 | 一种血液mRNA检测试剂盒及检测方法 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES |
JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
DK2090583T3 (da) | 1998-09-25 | 2011-09-12 | Yeda Res & Dev | Copolymer 1-relaterede polypeptider til anvendelse som molekylvægtsmarkører og til terapeutisk anvendelse |
WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
EP1128839A4 (en) | 1998-11-12 | 2002-10-09 | Yeda Res & Dev | PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD |
EP1261361B1 (en) | 2000-02-18 | 2006-06-14 | Yeda Research And Development Company, Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 (glatiramer acetate) |
US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
HUP0302333A3 (en) | 2000-06-05 | 2005-07-28 | Teva Pharma | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
ES2349033T3 (es) | 2001-12-04 | 2010-12-22 | Teva Pharmaceutical Industries, Ltd. | Procedimientos para la medida de la actividad del acetato de glatiramer. |
US8008258B2 (en) | 2003-01-21 | 2011-08-30 | Yeda Research And Development Co. Ltd. | Cop 1 for treatment of inflammatory bowel diseases |
CA2518079A1 (en) | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
PT1638589E (pt) | 2003-05-14 | 2014-06-12 | Teva Pharma | Terapia combinada com acetato de glatirâmero e mitoxantrona para o tratamento da esclerose múltipla |
US20050064483A1 (en) | 2003-08-28 | 2005-03-24 | Baylor College Of Medicine | Gene expression profiling technology for treatment evaluation of multiple sclerosis |
WO2005041933A1 (en) | 2003-10-31 | 2005-05-12 | Teva Pharmaceutical Industries, Ltd. | Nanoparticles for drug delivery |
AU2005218625A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
CA2571035A1 (en) | 2004-06-25 | 2006-01-12 | Id Biomedical Corporation Of Quebec | Compositions and methods for treating neurological disorders |
EP1796710A4 (en) | 2004-09-02 | 2010-05-26 | Teva Pharma | THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS |
SI1797109T1 (sl) | 2004-09-09 | 2016-07-29 | Yeda Research And Development Co., Ltd. | Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe |
ATE536363T1 (de) | 2004-09-09 | 2011-12-15 | Teva Pharma | Verfahren zur herstellung von mischungen von trifluoroacetyl-glatirameracetat bei verwendung von hydrobromsäure |
AU2006211510B8 (en) | 2005-02-02 | 2011-04-21 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
PL1848415T3 (pl) | 2005-02-17 | 2013-10-31 | Teva Pharma | Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego |
WO2006116602A2 (en) | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
WO2007030573A2 (en) | 2005-09-09 | 2007-03-15 | Yeda Research And Development Co. Ltd. | Polypeptides useful for molecular weight determinations |
WO2007081975A2 (en) | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
US20080131887A1 (en) * | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
AU2008330093A1 (en) | 2007-11-28 | 2009-06-04 | Yeda Research And Development Co., Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
SI2343982T1 (sl) * | 2008-09-17 | 2017-08-31 | Chiasma Inc. | Farmacevtski sestavki in metode povezane z dostavo |
EP2406396A2 (en) * | 2009-03-12 | 2012-01-18 | Brainco Biopharma, S.L. | A genotyping tool for improving the prognostic and clinical management of ms patients |
NZ577731A (en) * | 2009-06-16 | 2010-08-27 | Innate Therapeutics Ltd | Compositions and methods for treatment of multiple sclerosis |
US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
PL2275086T3 (pl) | 2009-07-15 | 2012-09-28 | Teva Pharma | Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania |
ES2612001T4 (es) | 2009-08-20 | 2018-02-07 | Yeda Research & Development Company, Ltd. | Terapia de baja frecuencia con acetato de glatirámero |
US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
NZ609938A (en) | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
KR101955247B1 (ko) * | 2011-07-01 | 2019-03-08 | 제온 코포레이션 | 2 차 전지용 다공막, 제조 방법, 및 용도 |
JP2014530819A (ja) * | 2011-10-10 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | 酢酸グラチラマーに対する臨床的応答性を予測するために有用な一塩基多形 |
EP2906719A4 (en) | 2012-10-10 | 2016-11-09 | Teva Pharma | PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE |
US20160193276A1 (en) | 2012-12-21 | 2016-07-07 | Teva Pharmaceutical Industries, Ltd. | Transmucosal delivery of glatiramer acetate |
AU2013361057A1 (en) | 2012-12-21 | 2015-07-30 | Teva Pharmaceutical Industries Ltd. | Oral transmucosal delivery of glatiramer acetate |
KR20150111945A (ko) | 2013-01-04 | 2015-10-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트 관련 완제의 특성조사 |
JP2016512552A (ja) | 2013-03-12 | 2016-04-28 | テバ ファーマシューティカル インダストリーズ リミティド | リツキシマブ導入療法とその後の酢酸グラチラマー療法 |
CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2014
- 2014-10-20 UY UY0001035790A patent/UY35790A/es not_active Application Discontinuation
- 2014-10-21 TW TW103136383A patent/TW201610166A/zh unknown
- 2014-10-21 EA EA201690759A patent/EA201690759A1/ru unknown
- 2014-10-21 JP JP2016522037A patent/JP2016540729A/ja not_active Withdrawn
- 2014-10-21 US US14/520,280 patent/US9702007B2/en active Active
- 2014-10-21 MX MX2016005003A patent/MX2016005003A/es unknown
- 2014-10-21 CN CN201480058055.6A patent/CN105658818A/zh active Pending
- 2014-10-21 EP EP14855499.1A patent/EP3060681A4/en not_active Withdrawn
- 2014-10-21 CA CA2926724A patent/CA2926724A1/en not_active Abandoned
- 2014-10-21 KR KR1020167013482A patent/KR20160098199A/ko not_active Application Discontinuation
- 2014-10-21 AU AU2014340247A patent/AU2014340247A1/en not_active Abandoned
- 2014-10-21 WO PCT/US2014/061647 patent/WO2015061367A1/en active Application Filing
-
2016
- 2016-03-28 IL IL244783A patent/IL244783A0/en unknown
-
2017
- 2017-01-19 US US15/410,091 patent/US20180002753A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2926724A1 (en) | 2015-04-30 |
EP3060681A1 (en) | 2016-08-31 |
IL244783A0 (en) | 2016-04-21 |
JP2016540729A (ja) | 2016-12-28 |
UY35790A (es) | 2015-05-29 |
WO2015061367A1 (en) | 2015-04-30 |
US20150110733A1 (en) | 2015-04-23 |
US9702007B2 (en) | 2017-07-11 |
KR20160098199A (ko) | 2016-08-18 |
US20180002753A1 (en) | 2018-01-04 |
EA201690759A1 (ru) | 2017-01-30 |
EP3060681A4 (en) | 2017-06-07 |
CN105658818A (zh) | 2016-06-08 |
AU2014340247A1 (en) | 2016-06-02 |
TW201610166A (zh) | 2016-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016005003A (es) | Marcadores geneticos predictivos de respuesta al acetato de glatiramero. | |
AU2018260866A1 (en) | Selective reduction of allelic variants | |
BR112014008752A2 (pt) | polimorfismos de nucleotídeos singulares úteis para predizer a resposta clínica para acetato de glatirâmero | |
MY154507A (en) | Gene Controlling Shell Phenotype in Palm | |
PH12015502273A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
SG10201804571TA (en) | Substituted nucleosides, nucleotides and analogs thereof | |
SG10201804835VA (en) | Substituted nucleosides, nucleotides and analogs thereof | |
NZ607996A (en) | Substituted nucleotide analogs | |
HK1200120A1 (en) | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells hs.459642 | |
MA40462A (fr) | Méthode de traitement de la dépression | |
WO2014058976A3 (en) | Biomarkers predictive for clinical response for glatiramer acetate | |
MX2021006626A (es) | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). | |
MX2017004127A (es) | Metodos para evaluar el riesgo de desarrollar cancer de mama. | |
AP2011005978A0 (en) | 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. | |
MY168778A (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
EP3626830A4 (en) | SINGLE NUCLEOTIDE POLYMORPHISM OF AN APOE PROMOTER RELATED TO ALZHEIMER'S MORBUS AND USE OF IT | |
WO2014124155A3 (en) | Methods for inducing cardiomyocyte proliferation | |
MX2016012718A (es) | Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina. | |
MX2021008091A (es) | Composicion que comprende artropodos y huevos de acaros astigmatidos. | |
AR104348A1 (es) | Polimorfismos de un solo nucleótido seleccionados que son predictivos de respuestas al acetato de glatirámero | |
WO2016209772A3 (en) | Snp arrays | |
AR098142A1 (es) | Marcadores genéticos que predicen la respuesta al acetato de glatiramer | |
GB2489180A (en) | Method of predicting capecitabine toxicity | |
UA96536U (uk) | Спосіб прогнозування зрощення перелому | |
UA104426U (uk) | Спосіб прогнозування зрощення перелому |